Comment by jddj

I was an early investor about 20 years ago (nothing to write home about) for a company in this space. Small molecule therapy though, not MRNA.

Very slow going, as is all speculative biotech stuff but it made it to approvals on the vetinary side (dogs and horses) and is sold in the US for those purposes. However, I believe the human trials are somewhere around P2 currently for H&N and other indications are even further back.

Only mentioning it because I still follow the annual reports, and I know that despite having no approvals they've treated a few patients via the various avenues that are available in Australia to people who have exhausted all other options.

The drug is tigilanol tiglate. It's had some success to date, with some immune responses in distal tumors after the initial application.

There is plenty of published research available, so please don't anyone take this comment as any kind of recommendation or advice.